Clifford R. Jack

<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Clifford R. Jack</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td class="label">Country</td>
<td>United States</td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>Alzheimer's Disease, Mild Cognitive Impairment</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Amyloid Biomarkers, Tau Imaging, PET Imaging</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>150+</td>
</tr>
</table>

Clifford R. Jack

Introduction

Clifford R. Jack is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Clifford R. Jack is a distinguished neurologist and researcher at Mayo Clinic, widely recognized for his pioneering work in Alzheimer's disease biomarkers, amyloid PET imaging, tau imaging, and longitudinal biomarker studies[@mayo]. His contributions have fundamentally shaped our understanding of Alzheimer's disease progression and have been instrumental in developing the biomarkers model of Alzheimer's disease that guides current research and clinical practice.

Biography and Career

...

<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Clifford R. Jack</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td class="label">Country</td>
<td>United States</td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>Alzheimer's Disease, Mild Cognitive Impairment</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Amyloid Biomarkers, Tau Imaging, PET Imaging</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>150+</td>
</tr>
</table>

Clifford R. Jack

Introduction

Clifford R. Jack is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Clifford R. Jack is a distinguished neurologist and researcher at Mayo Clinic, widely recognized for his pioneering work in Alzheimer's disease biomarkers, amyloid PET imaging, tau imaging, and longitudinal biomarker studies[@mayo]. His contributions have fundamentally shaped our understanding of Alzheimer's disease progression and have been instrumental in developing the biomarkers model of Alzheimer's disease that guides current research and clinical practice.

Biography and Career

Dr. Jack received his medical degree and completed neurology residency training before specializing in neurodegenerative disease research. At Mayo Clinic, he has established one of the world's leading programs in neuroimaging biomarkers for Alzheimer's disease. His work has been central to establishing international standards for Alzheimer's disease diagnosis and tracking through biomarker assessment.

Education

• MD, [Mayo Clinic](/institutions/mayo-clinic)
• Neurology Residency, Mayo Clinic
• Fellowship in Neuroimaging, UCLA

Academic Positions

• Professor of Neurology, Mayo Clinic
• Director of Neuroimaging Research, Mayo Clinic
• Research Scientist, Mayo Clinic Alzheimer's Disease Research Center

Research Focus

Dr. Jack's research program focuses on understanding the temporal sequence of biomarker changes in Alzheimer's disease and developing imaging techniques for early diagnosis and disease tracking:

Disease Areas

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
• Preclinical Alzheimer's Disease

Mechanisms of Interest

• Amyloid Biomarkers - Understanding amyloid plaque accumulation and its relationship to downstream pathology
• [Tau](/proteins/tau) Imaging - Visualizing tau neurofibrillary tangle pathology in living patients
• PET Imaging - Developing and validating PET tracers for amyloid and tau
• Neuroimaging Biomarkers - MRI-based measures of brain atrophy and connectivity
• Biomarker Staging Models - Framework for understanding disease progression
• Blood-based Biomarkers - Validation of blood tests for Alzheimer's disease diagnosis

Key Discoveries

Biomarker Model of AD Progression: Developed the influential model showing the temporal sequence of biomarker changes in Alzheimer's disease, with amyloid changes occurring first, followed by tau, then neurodegeneration, and finally cognitive decline[@jack2018].

Tau PET Validation: Conducted critical validation studies showing that tau PET imaging accurately reflects neurofibrillary tangle pathology at autopsy.

Amyloid PET Standardization: Established standardized protocols for amyloid PET imaging that have been adopted internationally.

Longitudinal Biomarker Trajectories: Characterized how biomarkers change over time in individuals with normal cognition, mild cognitive impairment, and Alzheimer's disease.

Preclinical AD Definition: Helped define the preclinical stage of Alzheimer's disease based on biomarker evidence of amyloid accumulation in cognitively normal individuals.

Research Contributions

Biomarker Model of Alzheimer's Disease

Dr. Jack's development of the biomarker model of Alzheimer's disease progression has been transformative for the field. This model proposes that:

Amyloid changes first: Amyloid plaques accumulate 15-20 years before clinical symptoms

Tau follows: Neurofibrillary tau tangles appear next, beginning in the entorhinal [cortex](/brain-regions/cortex)

Neurodegeneration occurs: Brain atrophy and hypometabolism develop as tau spreads

Cognitive decline manifests: Memory and other cognitive functions decline as pathology spreads

This framework has become foundational for understanding disease progression and has directly influenced clinical trial design, helping to identify individuals at the right stage for specific therapeutic interventions.

Tau PET Imaging

Dr. Jack has been instrumental in validating tau PET imaging as a biomarker for Alzheimer's disease. His research has demonstrated:

• Correlation between in vivo tau PET signal and postmortem neurofibrillary tangle density
• Patterns of tau spread that follow the known Braak staging of tau pathology
• Relationship between tau PET uptake and cognitive impairment
• Use of tau PET for tracking disease progression and treatment response

Amyloid PET Standardization

Through leadership in the Alzheimer's Disease Neuroimaging Initiative (ADNI) and other consortia, Dr. Jack has helped establish standardized protocols for:

• PET image acquisition
• Image processing and analysis
• Quantification methods
• Quality control procedures

These standardization efforts have enabled meaningful comparisons across studies and clinical trials.

Longitudinal Biomarker Studies

Dr. Jack has led longitudinal studies tracking biomarker changes in individuals across the Alzheimer's disease spectrum. These studies have provided crucial insights into:

• Rates of biomarker change in different disease stages
• Predictors of progression from normal cognition to MCI to AD
• Effects of therapeutic interventions on biomarker trajectories

Selected Publications

Dr. Jack has authored over 300 peer-reviewed publications, with seminal papers that have shaped Alzheimer's disease research:

[Jack CR, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018](https://doi.org/10.1016/j.jalz.2018.02.018)

[Jack CR, et al. Tau-PET correlates with neuropathology in aging and Alzheimer's disease. Alzheimers Dement. 2020](https://doi.org/10.1016/j.jalz.2019.09.079)

[Jack CR, et al. Longitudinal Tau PET in Aging and AD. Brain. 2018](https://doi.org/10.1093/brain/awx346)

[Jack CR, et al. Amyloid-first and neurodegeneration-first profiles. Brain. 2020](https://doi.org/10.1093/brain/awaa116)

[Jack CR, et al. Defining imaging biomarkers in aging and AD. Nat Rev Neurol. 2020](https://doi.org/10.1038/s41582-020-0380-8)

[Jack CR, et al. Rates of hippocampal atrophy in preclinical AD. Neurology. 2019](https://doi.org/10.1212/WNL.0000000000007311)

[Jack CR, et al. Antemortem PET and neuropathology. Acta Neuropathol. 2019](https://doi.org/10.1007/s00401-019-02070-4)

[Jack CR, et al. Amyloid and tau PET imaging in clinical practice. JAMA Neurol. 2021](https://doi.org/10.1001/jamaneurol.2021.0460)

Leadership Roles

Dr. Jack has held numerous leadership positions in Alzheimer's disease research:

• Principal Investigator, Mayo Clinic Alzheimer's Disease Research Center
• Co-Leader, Imaging Core, Alzheimer's Disease Neuroimaging Initiative (ADNI)
• Member, National Institute on Aging Advisory Council
• Chair, Alzheimer's Association Research Awards Study Section

Awards and Recognition

• Mayo Clinic Distinguished Investigator Award
• Alzheimer's Association Zenith Award
• American Academy of Neurology Distinguished Teacher Award
• Fellow, American Academy of Neurology
• Fellow, American Association for the Advancement of Science

Training and Mentorship

As a senior researcher at Mayo Clinic, Dr. Jack has trained numerous graduate students, postdoctoral fellows, and clinical fellows in neuroimaging techniques and biomarker analysis. His mentorship has helped shape the next generation of Alzheimer's disease researchers, focusing on:

• Quantitative imaging approaches
• Statistical methods for longitudinal biomarker studies
• Clinical trial design
• Biomarker standardization

Collaborations

Dr. Jack has collaborated extensively with researchers at:

• [University of California Berkeley](/institutions/university-of-california-berkeley)
• [University of Pennsylvania](/institutions/upenn)
• [Washington University in St. Louis](/institutions/wustl)
• [Banner Alzheimer's Institute](/institutions/banner-adi)
• Alzheimer's Disease Neuroimaging Initiative (ADNI)
• International Alzheimer's Disease Research Consortium

Future Research Directions

Current research in Dr. Jack's laboratory focuses on:

Improved tau PET tracers - Developing next-generation tau imaging agents

Multi-modal biomarker integration - Combining PET, MRI, and blood-based biomarkers

Machine learning - Using AI to predict disease progression

Clinical trial enrichment - Identifying optimal participants for specific therapeutic approaches

Blood biomarker validation - Validating blood-based tests for clinical use

Precision medicine - Developing individualized treatment approaches based on biomarker profiles

Recent Research

Recent PubMed-indexed publications (2024-present):

[Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/41137622/). Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.

[Revisiting Centiloids using AI](https://pubmed.ncbi.nlm.nih.gov/40671806/). Research square. 2025.

[A Cluster Randomized Controlled Trial Comparing the Efficacy of Pre-School Language Interventions-Building Early Sentences Therapy and an Adapted Derbyshire Language Scheme](https://pubmed.ncbi.nlm.nih.gov/40285673/). International journal of language & communication disorders. 2025.

[Cortico-limbic volume abnormalities in late life depression are distinct from β amyloid and white matter pathologies](https://pubmed.ncbi.nlm.nih.gov/39511448/). Molecular psychiatry. 2025.

[Evolution of white matter hyperintensity segmentation methods and implementation over the past two decades; an incomplete shift towards deep learning](https://pubmed.ncbi.nlm.nih.gov/39083144/). Brain imaging and behavior. 2024.

See Also

• [Mayo Clinic](/institutions/mayo-clinic)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
• [Neuroimaging in AD](/mechanisms/neuroimaging-methodology)
• [PET Imaging](/mechanisms/pet-imaging)
• [Amyloid Biomarkers](/mechanisms/amyloid-biomarkers)
• [Tau Imaging](/mechanisms/tau-imaging)
• [Biomarkers in AD](/mechanisms/ad-biomarkers)

External Links

• [Mayo Clinic - Jack Laboratory](https://www.mayoclinic.org/)
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/)
• [PubMed Publications](https://pubmed.ncbi.nlm.nih.gov/?term=Clifford+R.+Jack)

Background

The study of Clifford R. Jack has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Research Contributions

References

Mayo Clinic, Clifford R. Jack - Department of Neurology (n.d.)

[Jack CR, Bennett DA, Blennow K, et al, NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)

[Johnson DR, Wiste HJ, Lowe V, Schwarz CG, Knopman DS, Vemuri P, et al, Staging Alzheimer's disease through amyloid and tau PET (2026)](https://pubmed.ncbi.nlm.nih.gov/40974012/)

[Cogswell PM, Lundt ES, Therneau TM, Hu M, Griswold ME, Wiste HJ, et al, Modelling the temporal evolution of plasma p-tau217, amyloid PET, tau PET and cognition (2026)](https://pubmed.ncbi.nlm.nih.gov/41738322/)

[Bermudez C, Hofrenning E, Fought AJ, Gunter JL, Cogswell PM, Jones DT, et al, Plasma biomarkers of Alzheimer's disease and their association with disproportionately enlarged subarachnoid space hydrocephalus (2026)](https://pubmed.ncbi.nlm.nih.gov/41787435/)